^
Association details:
| Biomarker: | CTNNB1 mutation |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
B-catenin mutations and the response of advanced hepatocellular carcinoma to immune checkpoint inhibitors.
Published date:
05/26/2022
Excerpt:
CONTRADICTING EVIDENCE: Median progression-free survival (PFS), 3-month PFS, 6-month PFS, and the disease control rate (DCR) on ICI therapy were compared between B-catenin mutation (BCM) and B-catenin wild-type (BCWT) groups….For best response, 33% of patients with BCM HCC achieved stable disease compared to 67% of patients with BCWT HCC. No patients in our cohort achieved partial or complete response. The DCR for BCM HCC was 33% and the DCR for BCWT HCC was 67%.
DOI:
10.1200/JCO.2022.40.16_suppl.e16124
Source:
Title:
CTNNB1 Alternation Is a Potential Biomarker for Immunotherapy Prognosis in Patients With Hepatocellular Carcinoma
Published date:
10/28/2021
Excerpt:
In this study, we found CTNNB1-MUT to be a potential biomarker for HCC immunotherapy patients, because it identified those patients are less likely to benefit from ICIs.
DOI:
10.3389/fimmu.2021.759565
